Dennis J. Slamon
University of California, Los Angeles · 987 works · 101,081 citations · h-index 126
Top works
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
- Differential expression of cellular oncogenes during pre- and postnatal development of the mouse
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
- Expression of Cellular Oncogenes in Human Malignancies
- Expression of a multidrug-resistance gene in human tumors and tissues.
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
- Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
- Palbociclib and Letrozole in Advanced Breast Cancer
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
- HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
- PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
- The addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2-overexpressing metastatic breast cancer (HER2+ MBC) markedly increases anti-cancer activity: A randomized, multinational controlled phase II trial.
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
- Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs